Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

被引：1

作者：

Marin-Aguilera, M. ^{[1
]}

Jares, P. ^{[2
,3
]}

Sanfeliu, E. ^{[2
]}

Villacampa, G. ^{[4
,5
]}

Hernandez-lllan, E. ^{[3
]}

Martinez-Puchol, A. I. ^{[3
]}

Shankar, S. ^{[6
]}

Gonzalez-Farre, B. ^{[2
]}

Waks, A. G. ^{[6
]}

Braso-Maristany, F. ^{[1
,7
]}

Pardo, F.

Manning, D. K. ^{[6
]}

Abery, J. A. ^{[8
]}

Curaba, J. ^{[8
]}

Moon, L.

Gordon, O. ^{[8
]}

Galvan, P. ^{[1
,7
]}

Wachirakantapong, P. ^{[6
]}

Castillo, O. ^{[7
]}

Nee, C. M. ^{[6
]}

Blasco, P. ^{[7
]}

Senevirathne, T. H. ^{[6
]}

Sirenko, V. ^{[7
]}

Martinez-Saez, O. ^{[7
,9
,10
]}

Aguirre, A. ^{[7
]}

Krop, I. E. ^{[11
]}

Li, Z. ^{[12
,13
]}

Spellman, P. ^{[14
]}

Metzger Filho, O. ^{[6
,13
]}

Polyak, K. ^{[12
,13
]}

Michaels, P. ^{[6
]}

Puig-Butille, J. A. ^{[3
]}

Vivancos, A. ^{[15
]}

Matito, J. ^{[1
,15
]}

Buckingham, W. ^{[1
]}

Perou, C. M. ^{[16
]}

Villagrasa-Gonzalez, P. ^{[1
]}

Prat, A. ^{[1
,7
,9
,11
,17
]}

Parker, J. S. ^{[16
]}

Pare, L. ^{[1
]}

机构：

[1] Reveal Genom SL, Sci Dept, Carrer Villarroel 170,Escala 2,Planta 5, Barcelona 08036, Spain

[2] Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain

[3] Hosp Clin Barcelona, Mol Biol Core, Barcelona, Spain

[4] SOLTI Breast Canc Res Grp, Barcelona, Spain

[5] Vall dHebron Inst Oncol, Stat Unit, Barcelona, Spain

[6] Brigham & Womens Hosp, Ctr Adv Med Diagnost, Dept Pathol, Boston, MA USA

[7] Translat Genom & Targeted Therapies Solid Tumors, IDIBAPS, Dept Pathol, Barcelona, Spain

[8] Eremid Genom Serv LLC, Kannapolis, NC USA

[9] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[10] Univ Barcelona, Dept Med, Barcelona, Spain

[11] Yale Canc Ctr, New Haven, CT USA

[12] Dana Farber Canc Inst, Boston, MA USA

[13] Harvard Med Sch, Boston, MA USA

[14] Oregon Hlth & Sci Univ, Portland, OR USA

[15] Vall dHebron Inst Oncol VHIO, Canc Genom Core, Barcelona, Spain

[16] Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC USA

[17] IOB Quiron Salud, Breast Canc Unit, Barcelona, Spain

来源：

ESMO OPEN | 2024年 / 9卷 / 03期

基金：

欧盟地平线“2020”;

关键词：

HER2DX; breast cancer; gene expression; RNA; analytical validation; OUTCOMES;

D O I：

10.1016/j.esmoop.2024.102903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: HER2DX, a multianalyte genomic test, has been clinically validated to predict breast cancer recurrence risk (relapse risk score), the probability of achieving pathological complete response post-neoadjuvant therapy (pCR likelihood score), and individual ERBB2 messenger RNA (mRNA) expression levels in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This study delves into the comprehensive analysis of HER2DX's analytical performance. Materials and methods: Precision and reproducibility of HER2DX risk, pCR, and ERBB2 mRNA scores were assessed within and between laboratories using formalin-fixed paraffin-embedded (FFPE) tumor tissues and purified RNA. Robustness was appraised by analyzing the impact of tumor cell content and protocol variations including different instruments, reagent lots, and different RNA extraction kits. Variability was evaluated across intratumor biopsies and genomic platforms [RNA sequencing (RNAseq) versus nCounter], and according to protocol variations. Results: Precision analysis of 10 FFPE tumor samples yielded a maximal standard error of 0.94 across HER2DX scores (1-99 scale). High reproducibility of HER2DX scores across 29 FFPE tumors and 20 RNAs between laboratories was evident (correlation coefficients >0.98). The probability of identifying score differences >5 units was <5.2%. No significant variability emerged based on platform instruments, reagent lots, RNA extraction kits, or TagSet thaw/freeze cycles. Moreover, HER2DX displayed robustness at low tumor cell content (10%). Intratumor variability across 212 biopsies (106 tumors) was <4.0%. Concordance between HER2DX scores from 30 RNAs on RNAseq and nCounter platforms exceeded 90.0% (Cohen's k coefficients > 0.80). Conclusions: The HER2DX assay is highly reproducible and robust for the quantification of recurrence risk, pCR likelihood, and ERBB2 mRNA expression in early-stage HER2-positive breast cancer.

引用

页数：11

共 50 条

[21] Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
Kourie, Hampig Raphael
El Rassy, Elie
Clatot, Florian
de Azambuja, Evandro
Lambertini, Matteo
ONCOTARGETS AND THERAPY, 2017, 10 : 3363 - 3372
[22] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
Plosker, Greg L.
Keam, Susan J.
BIODRUGS, 2006, 20 (04) : 259 - 262
[23] PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Agostinetto, Elisa
Ameye, Lieveke
Martel, Samuel
Aftimos, Philippe
Ponde, Noam
Maurer, Christian
El-Abed, Sarra
Wang, Yingbo
Vicente, Malou
Chumsri, Saranya
Bliss, Judith
Kroep, Judith
Colleoni, Marco
Petrelli, Fausto
Del Mastro, Lucia
Moreno-Aspitia, Alvaro
Piccart, Martine
Paesmans, Marianne
de Azambuja, Evandro
Lambertini, Matteo
NPJ BREAST CANCER, 2022, 8 (01)
[24] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
Greg L. Plosker
Susan J. Keam
BioDrugs, 2006, 20 : 259 - 262
[25] Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab plus /- pertuzumab (TCH/TCHP): a correlative analysis from a multicenter academic study
Bueno-Muino, Coralia
Echavarria, Isabel
Lopez-Tarruella, Sara
Marta, Roche-Molina
Del Monte-Millan, Maria
Massarrah, Tatiana
Gilarranz, Yolanda Jerez
Herrero, Blanca
Gamez, Salvador
Marquez-Rodas, Ivan
Cebollero-Presmanes, Maria
Manuel, Nevado Santos
Barrio, Pilar de la Morena
de la Pena, Francisco Ayala
Garcia-Saenz, Jose Angel
Anton, Fernando Moreno
Lescure, Alvaro Rodriguez
Quintanar, Teresa
Malon-Gimenez, Diego
Rodriguez-Lajusticia, Laura
Garcia, Ana Isabel Ballesteros
Torres, Dulce Banon
Villarejo, Lucia
Lobato, Nerea
Arias, Ainhoa
Ocana, Inmaculada
Alvarez, Enrique
Pare, Laia
Marin-Aguilera, Mercedes
Galvan, Patricia
Braso-Maristany, Fara
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Prat, Aleix
Martin, Miguel
CANCER RESEARCH, 2023, 83 (05)
[26] HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Braso-Maristany, Fara
Griguolo, Gaia
Chic, Nuria
Pascual, Tomas
Pare, Laia
Maues, Julia
Galvan, Patricia
Dieci, Maria Vittoria
Miglietta, Federica
Giarratano, Tommaso
Martinez-Saez, Olga
Marin-Aguilera, Mercedes
Schettini, Francesco
Conte, Benedetta
Angelats, Laura
Vidal, Maria
Adamo, Barbara
Munoz, Montserrat
Sanfeliu, Esther
Gonzalez, Blanca
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Conte, PierFranco
Prat, Aleix
Guarneri, Valentina
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (03): : 332 - 336
[27] Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer
Kim, Yong-Seok
Sun, Der Sheng
Ahn, Juneyoung
Kim, Yongseon
Yoon, Jung-Sook
Won, Hye Sung
CANCERS, 2022, 14 (15)
[28] Neratinib for the treatment of HER2-positive early stage breast cancer
Echavarria, Isabel
Lopez-Tarruella, Sara
Marquez-Rodas, Ivan
Jerez, Yolanda
Martin, Miguel
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
[29] Optimal treatment of early stage HER2-positive breast cancer
Pernas, Sonia
Barroso-Sousa, Romualdo
Tolaney, Sara M.
CANCER, 2018, 124 (23) : 4455 - 4466
[30] Personalized treatment for early stage HER2-positive breast cancer
Prat, A.
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →